Terasaki Institute for Biomedical Innovation and HTL Biotechnology Announce Memorandum of Understanding for Research in Translational Biomaterials
News provided by
Share this article
Share this article
LOS ANGELES, May 7, 2021 /PRNewswire/ The Terasaki Institute for Biomedical Innovation (TIBI), a research institute at the frontier of personalized and precision medicine, and HTL Biotechnology, the world leader in using hyaluronic acid and other biopolymers for biotechnology solutions, announce their Memorandum of Understanding to explore the creation of a joint research program. This program focuses on biomaterials for translational projects; it would combine TIBI s microneedle and bioprinting technologies with HTL s expertise in biopolymers for aesthetics, dermatology, ophthalmology, rheumatology, tissue engineering and drug delivery applications.
Scientific collaboration with China under the microscope in Canada theglobeandmail.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theglobeandmail.com Daily Mail and Mail on Sunday newspapers.
Terasaki Institute for Biomedical Innovation Announces Inaugural Leadership Board
News provided by
Share this article
Share this article
LOS ANGELES, April 27, 2021 /PRNewswire/ The Terasaki Institute for Biomedical Innovation announces the establishment of the inaugural Leadership Board. This board brings together individuals passionate about research and technology to enhance and create practical solutions for patient health and wellness and provides vital opportunity to support the growth of the Institute. This board includes distinguished individuals who will leverage their expertise to provide strategic guidance on innovation, research areas, promote key initiatives, and support the mission and vision of the Institute.
Joining the newly established Leadership Board is Sultana Afdhal, George Ayoub, Alex Goldberg, Stephen Ibaraki, Frank Litvack, Asad M. Madni, David Nazarian, and Douglas A. Wilson.
E-Mail
(LOS ANGELES) - The National Institutes of Health has jointly awarded a $3.9 million grant to Ali Khademhosseini, Ph.D., director and CEO of the Terasaki Institute for Biomedical Innovation (TIBI), and Rami Oklu, Ph.D., M.D., of the Mayo Clinic. The grant will be used to develop innovative drug delivery methods to treat liver cancer. TIBI, a leader in the field of bioengineering and personalized healthcare solutions, will draw upon their extensive experience with biomaterials to create more effective ways to target and destroy tumor cells. The project will also rely on the collaboration and clinical expertise of Prof. Oklu, a specialist in the treatment of oncologic patients.